Holen Sie sich die Stockscreener-App
10.16
1.09%
0.11
Handel nachbörslich:
10.25
0.09
+0.89%
Promis Neurosciences Inc Aktie (PMN) Neueste Nachrichten
ProMIS Neurosciences (PMN) Dips 3.54% as Biotech Stock Tests Key Support ZonePrice Action Signals - newsline.com
All You Need to Know About Promis Neurosciences (PMN) Rating Upgrade to Buy - Yahoo Finance
Wall Street Analysts Think Promis Neurosciences (PMN) Could Surge 231.78%: Read This Before Placing a Bet - Yahoo Finance
ProMIS Neurosciences Inc. (PMN) Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline Amid Pipeline AdvancesAnalyst Drop Coverage - newsline.com
H.C. Wainwright reiterates Buy on ProMIS Neurosciences stock By Investing.com - Investing.com Canada
PMN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $18 - GuruFocus
H.C. Wainwright Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Maintains Target Price $18 - Moomoo
PMN Q1 2026 Earnings: Narrower-than-Expected Loss Amid Ongoing Clinical DevelopmentROA Comparison - newsline.com
ProMIS Neurosciences Inc Annual Shareholders Meeting Transcript - GuruFocus
PMN Q1 2026 Earnings: EPS Surprises to the Upside Despite Lack of RevenueMargin Guidance - newsline.com
ProMIS Neurosciences (PMN) Slips 3.3% as Biotech Sentiment Shifts – Key Support Holds at $9.56Median Line - newsline.com
ProMIS Neurosciences (PMN) Faces Bearish Pressure as Shares Slide 3.70%Value Stock Ideas - newsline.com
PMN Technical Analysis | Trend, Signals & Chart Patterns | PROMIS NEUROSCIENCES INC (NASDAQ:PMN) - ChartMill
ProMIS Neurosciences to Participate in Upcoming Conferences in June - The Manila Times
Alzheimer’s drug trial data from ProMIS expected in early Q3 2026 - Stock Titan
ProMIS Neurosciences (PMN) Gains Momentum as Shares Test Key Resistance Near $11.29Moving Average Crossovers - newsline.com
ProMIS Neurosciences (PMN) Slips 5.65% as Shares Test Key Support LevelWave Alternation - newsline.com
PMN Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Progress in Neurodegenerative PipelineRevenue Breakdown Analysis - The Legal Advocate
PMN Q1 2026 Earnings: Narrower-than-expected Loss; Stock Gains on Pipeline ProgressPretax Income Report - Newser
Yu Fan's ProMIS Neurosciences Inc(PMN) Holding History - GuruFocus
ProMIS Neurosciences (PMN) director granted 16,500 options at $10.77 strike price - Stock Titan
ProMIS Neurosciences (PMN) director granted options on 16,500 shares - Stock Titan
ProMIS Neurosciences (PMN) CEO awarded 160,000 options at $10.77 strike - Stock Titan
ProMIS Neurosciences (PMN) director awarded long-dated stock options - Stock Titan
ProMIS Neurosciences (PMN) awards CSO 50,000 options vesting over 4 years - Stock Titan
Executive at ProMIS (PMN) receives 18,167 stock options expiring 2036 - Stock Titan
ProMIS Neurosciences (PMN) director receives 16,500 stock options grant - Stock Titan
ProMIS Neurosciences (PMN) CDO awarded 50,000 stock options - Stock Titan
Director at ProMIS Neurosciences (PMN) receives new option grants as board compensation - Stock Titan
PMN Q1 2026 Earnings: Narrowed EPS Surprise Drives Positive Stock ReactionDividend Earnings Report - The Legal Advocate
ProMIS Neurosciences (NASDAQ: PMN) shareholders approve larger 2025 stock option plan - Stock Titan
Analysts’ Top Healthcare Picks: ProMIS Neurosciences (PMN), Evolent Health (EVH) - The Globe and Mail
Great Point, Dr. Jay and Nordahl report 9.99% stake in PROMIS (PMN) - Stock Titan
Wellington Group discloses 895,871-share holding in ProMIS (PMN) - Stock Titan
ProMIS Neurosciences Inc. Q1 2026 Financial Results, Forward-Looking Statements, and Risk Factors Overview - Minichart
TradingKey - TradingKey
ProMIS Neurosciences Releases Q1 2026 Financial Results - AlphaStreet
ProMIS Neurosciences Reports Q1 2026 Results, Advances Alzheimer’s PMN310 Trial and Secures $175M Financing - Minichart
ProMIS Neurosciences (PMN) Q1 2026 Earnings: EPS N/A, Revenue N/ - GuruFocus
ProMIS (PMN) Targets Alzheimer's Treatment with Promising Trial and Funding - GuruFocus
ProMIS Neurosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
ProMIS Neurosciences Inc. Q1 2026: Net income $(8.24M), Diluted EPS $(1.26) — 10-Q Summary - TradingView
ProMIS Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] ProMIS Neurosciences Inc. Quarterly Earnings Report - Stock Titan
ProMIS Neurosciences (Nasdaq: PMN) boosts cash with $175M financing and advances PMN310 - Stock Titan
ProMIS Neurosciences Inc. Closes PIPE Financing of Up to $175 Million to Support Alzheimer's Disease Clinical Trial - Quiver Quantitative
Alzheimer's trial fully enrolled as ProMIS funds work through 2027 - Stock Titan
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights - ChartMill
ProMIS Neurosciences (PMN) owners report 181,632 shares (2.0%) in 13G/A amendment - Stock Titan
Insider Purchase: Director at $PMN Buys 4,000 Shares - Moomoo
ProMIS Neurosciences to execute 1-for-25 reverse stock split - MSN
ProMIS Neurosciences Shares Advance After New Data Supports Alzheimer’s Trial Strategy - MSN
PMN Price Today: ProMIS Neurosciences Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Director Kirwin’s entity buys 4,000 ProMIS (PMN) shares at $11.33 - Stock Titan
PMN ProMIS Neurosciences Inc. Common Shares (ON) posts wider than expected Q4 2025 loss but still notches small share price gain today.Equity Raise - UBND thành phố Hải Phòng
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):